BLUE BELL, Pa.,
June 13, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr.
Niranjan Sardesai, COO, will participate on a panel of senior vaccine experts at the 2012 BIO International Convention,the largest global event for the biotechnology industry. Dr.
J. Joseph Kim, President and CEO, will present an overview of the company at the Marcum Microcap Conference, which is designed for investors interested in micro-cap companies.
2012 BIO International Convention
June 18-21, 2012Boston Convention & Exhibition Center, MA
Leveraging New Development Paradigms to Address Infectious Diseases in the 21st Century Session ID: 1201
Tuesday, June 19
10:00 AM - 11:30 a.m. ET
TopicThe "one bug, one vaccine" paradigm worked for years and eradicated some major diseases. Today's bugs are pathogens that either change rapidly or have many serotypes—and they command innovation throughout the vaccine value chain. The panel will discuss 21st century needs and the innovations necessary for new vaccines.
- Moderator: Stanley Plotkin Consultant in Vaccinology, Sanofi Pasteur
- Jeffrey AlmondVice President, Discovery Research and External R&D, Sanofi Pasteur
- Anthony Ford-HutchinsonIndependent Consultant, Ford-Hutchinson Consulting Ltd. Retired Merck Senior Vice President, Vaccines Research and Development
- Christian W. MandlVP, Head of US Research, Novartis Vaccine & Diagnostics, Inc. and Global Head for all viral vaccine research projects
- Regina RabinovichDirector, Enteric & Diarrheal Diseases and Pneumonia & Interim Director Malaria, Global Health Program, Bill & Melinda Gates Foundation
Marcum Microcap Investor Conference
June 20, 2012
- Niranjan Sardesai Chief Operating Officer, Inovio Pharmaceuticals
45 East 45
Street, The Roosevelt Hotel
New York City
Wednesday, June 20
12:30 p.m. ET
J. Joseph Kim
, PhD, President and CEO
A live and archived webcast of the presentation will be accessible on Inovio's website at
About Marcum Microcap Conference
The Marcum MicroCap conference is designed for investors interested in the micro-cap arena. The event is free to attend for qualified investors and the company will make a formal presentation and be available for one-on-ones. For full event details, please
About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. The firm has full service offices strategically located in 23 offices throughout the US as well as
. Marcum is a member of the
, the gateway to a group of organizations that provide a variety of professional services.
About CCG Investor Relations
CCG is a leading global investor relations and strategic communications consulting firm providing a complete range of investor communications, counseling, and IT and data solutions through its global network to over 100 clients across multiple capital markets. The agency has offices in
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the
University of Pennsylvania
, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended March 31, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
, Inovio Pharmaceuticals 858-410-3101
, Inovio Pharmaceuticals 267-440-4211
SOURCE Inovio Pharmaceuticals Inc.